Journal
ANTIVIRAL RESEARCH
Volume 142, Issue -, Pages 83-122Publisher
ELSEVIER
DOI: 10.1016/j.antiviral.2017.02.014
Keywords
Direct-acting antivirals; NS3/4A drugs; NS5A drugs; NS5B drugs
Categories
Funding
- National Nature Science Foundation of China [31571368]
- Project of Innovation-driven Plan of Central South University [2016CX031]
Ask authors/readers for more resources
One of the most exciting developments in antiviral research has been the discovery of the direct-acting antivirals (DAAs) that effectively cure chronic hepatitis C virus (HCV) infections. Based on more than 100 clinical trials and real-world studies, we provide a comprehensive overview of FDA-approved therapies and newly discovered anti-HCV agents with a special focus on drug efficacy, mechanisms of action, and safety. We show that HCV drug development has advanced in multiple aspects: (i) interferon-based regimens were replaced by interferon-free regimens; (ii) genotype-specific drugs evolved to drugs for all HCV genotypes; (iii) therapies based upon multiple pills per day were simplified to a single pill per day; (iv) drug potency increased from moderate (similar to 60%) to high (>90%) levels of sustained virologic responses; (v) treatment durations were shortened from 48 to 12 or 8 weeks; and (vi) therapies could be administered orally regardless of prior treatment history and cirrhotic status. However, despite these remarkable achievements made in HCV drug discovery, challenges remain in the management of difficult-to-treat patients. (C) 2017 Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available